ACIFORMULA
ACI Formulations PLC · Pharmaceuticals and Chemicals · Cat ADSE Hexagon
Stands out for constructive price action and a strong earnings record, held back by little dividend.
Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.
Risks & rewards
Risks (1)
- ⚠ Thin free float — prone to sharp swings
Rewards (2)
- ✓ Financial health improving
- ✓ Earnings trending up
Score breakdown
Price history & performance
Shareholder returns vs DSEX
ACIFORMULA underperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.
Volatility
Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.
Technical read
Valuation
Ownership
Thin free float (9.75%) — a small pool of tradable shares can move sharply on modest volume.
Share structure
Financials
Recent P/E ratio
Based on the latest un-audited financial statements. Descriptive only.
Dividend history
Earnings & NAV
Quarterly EPS — FY2026
From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.
Levels
Resistance
Support
Historical bounce zones
Sector peers
Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.
Historical outlook
Based on how similar setups behaved historically — not a prediction of what will happen.
Signals: RSI>70 overbought
Reference levels
Descriptive reference points from the analysis — not instructions to buy or sell.
Elevated (score 140) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: ACCUMULATION (11% >200-MA, flow ACC). [fundamentals SUSTAINABLE, payout 32.0%, yield 1.6%]
Market activity
Block activity
Block trade ৳0.7M (1 trade), 0.8× normal public volume, institutional ownership +0.6pp.